Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolinapant - Astex Pharmaceuticals

Next Previous
X
Search
Drug Profile

Tolinapant - Astex Pharmaceuticals

Alternative Names: ASTX 660

Latest Information Update: 30 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals; Emory University; Otsuka Pharmaceutical
  • Class Antineoplastics; Fluorinated hydrocarbons; Ketones; Morpholines; Piperazines; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lymphoma; Solid tumours
  • Phase I/II Peripheral T-cell lymphoma; T-cell lymphoma
  • Phase I Colorectal cancer; Squamous cell cancer
  • Preclinical Precursor T-cell lymphoblastic leukaemia-lymphoma
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 30 Sep 2024 National Cancer Institute plans a phase I trial for Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Unresectable/Inoperable, Second-line therapy or greater) in September 2024 (PO) (NCT06590558)
  • 01 May 2024 National Cancer Institute plans phase-I/II trial for Ovarian cancer (Second-line therapy or greater, Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in June 2024 (PO)(NCT06393751)
  • 05 Apr 2024 Efficacy, safety and pharmacodynamics data from the phase I ASTEROI trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top